Quick Answer
ORAMED PHARMACEUTICALS INC. reported Operating Income Loss of -$15.09 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed a decrease of -18.1% in Operating Income Loss from 2024 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ORAMED PHARMACEUTICALS INC.'s Operating Income Loss has declined by 519.6%.
- Historical annual values: Fiscal year 2025: -$15.09 million | Fiscal year 2024: -$12.78 million | Fiscal year 2023: -$15.77 million | Fiscal year 2022: -$40.60 million | Fiscal year 2021: -$24.22 million | Fiscal year 2020: -$11.76 million | Fiscal year 2019: -$14.63 million | Fiscal year 2018: -$13.53 million | Fiscal year 2017: -$10.77 million | Fiscal year 2016: -$10.01 million | Fiscal year 2015: -$7.38 million | Fiscal year 2014: -$5.91 million | Fiscal year 2013: $4.30 million | Fiscal year 2012: -$2.88 million | Fiscal year 2011: -$2.44 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: